Extensive research has shown that inflammation and activation of the immune system are involved in the pathophysiological processes of brain injury after both ischemic and hemorrhagic stroke. After an ischemic stroke there is an increase in inflammatory cytokines (e.g. IL-6, IL-8, TNFa, IL-1ß), cell adhesion molecules (e.g. SELE, VCAM1, ICAM1), reactive oxygen species, parallel to an activation of microglia, endothelial cells and peripheral leukocytes, that result in recruitment, adhesion and infiltration of peripheral leukocytes into the brain, contributing to the appearance of complications that result in poor outcomes. This inflammatory response is similar following hemorragic stroke, with the difference that all blood components are introduced directly into the brain at the onset of hemorraghe and additionally iron-containing proteins released by hemolysis, which are also potent inflammatory stimuli. Furthermore, the inflammatory state is also related to stroke recurrence.
Various anti-inflammatory strategies have been used to reduce inflammation in ischemic and hemorragic stroke. However, it is unclear whether the functional outcome is improved and the search for more promising therapies continues. Their role in preventing new stroke is also an interesting area of research.
The aim of this Research Topic is to gather scientific contributions (Research Articles or Reviews) from any groups working on inflammation and stroke, but is also open to other inflammatory states, such as atherosclerosis, chronic hypertension, obesity, and diabetes. Scientific topics are listed below, but are not limited to:
1) The inflammatory response poststroke
2) New potential targets to limit inflammation in human and experimental stroke
3) Sophisticated therapies that prevent secondary injury and the appearance of complications that result in poor outcomes in patients
4) Inflammatory Biomarkers and Prediction of Outcome
Topic Editor Lourdes M Varela received financial support from Salena Medical S.L. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Extensive research has shown that inflammation and activation of the immune system are involved in the pathophysiological processes of brain injury after both ischemic and hemorrhagic stroke. After an ischemic stroke there is an increase in inflammatory cytokines (e.g. IL-6, IL-8, TNFa, IL-1ß), cell adhesion molecules (e.g. SELE, VCAM1, ICAM1), reactive oxygen species, parallel to an activation of microglia, endothelial cells and peripheral leukocytes, that result in recruitment, adhesion and infiltration of peripheral leukocytes into the brain, contributing to the appearance of complications that result in poor outcomes. This inflammatory response is similar following hemorragic stroke, with the difference that all blood components are introduced directly into the brain at the onset of hemorraghe and additionally iron-containing proteins released by hemolysis, which are also potent inflammatory stimuli. Furthermore, the inflammatory state is also related to stroke recurrence.
Various anti-inflammatory strategies have been used to reduce inflammation in ischemic and hemorragic stroke. However, it is unclear whether the functional outcome is improved and the search for more promising therapies continues. Their role in preventing new stroke is also an interesting area of research.
The aim of this Research Topic is to gather scientific contributions (Research Articles or Reviews) from any groups working on inflammation and stroke, but is also open to other inflammatory states, such as atherosclerosis, chronic hypertension, obesity, and diabetes. Scientific topics are listed below, but are not limited to:
1) The inflammatory response poststroke
2) New potential targets to limit inflammation in human and experimental stroke
3) Sophisticated therapies that prevent secondary injury and the appearance of complications that result in poor outcomes in patients
4) Inflammatory Biomarkers and Prediction of Outcome
Topic Editor Lourdes M Varela received financial support from Salena Medical S.L. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
